Merck’s once-monthly oral PCSK9 inhibitor enlicitide decanoate demonstrated robust and clinically meaningful reductions in LDL cholesterol levels across two phase III Coralreef studies in hyperlipidemia patients. This potential best-in-class candidate aims to compete in a crowded lipid-lowering market with strong efficacy in cardiovascular risk management.